Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

RXi Pharmaceuticals logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Advanced Chart

Key Stats

Today's Range
$1.95
$2.03
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
136,481 shs
Average Volume
1.73 million shs
Market Capitalization
$8.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines

RXII Stock Analysis - Frequently Asked Questions

RXi Pharmaceuticals Co. (NASDAQ:RXII) released its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Endologix (ELGX), Auris Medical (EARS), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
8/14/2018
Today
6/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RXII
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.45 million
Net Margins
-4,990.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
2.60

Miscellaneous

Free Float
N/A
Market Cap
$8.76 million
Optionable
Not Optionable
Beta
2.07
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:RXII) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners